Last reviewed · How we verify

NCT03012282

CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer

Terminated NA Last updated 6 July 2022
What this trial tests

NA trial testing Computed Tomography Perfusion Imaging in Pancreatic Ductal Adenocarcinoma in 70 participants. Terminated before completion.

Timeline
22 June 2017
Primary endpoint
1 June 2022
1 June 2022

Quick facts

Lead sponsorUniversity of Washington
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment70
Start date22 June 2017
Primary completion1 June 2022
Estimated completion1 June 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Washington

Who can join

18 and older, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot clinical trial studies how well computed tomography (CT) perfusion images work in assessing treatment response in patients with pancreatic cancer. Analyzing specific measurements on the CT perfusion images may help doctors better determine how a tumor responds to chemotherapy and/or radiation therapy and may help guide treatment for patients with pancreatic cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Computed Tomography Perfusion Imaging

Trials testing the same drug.

Other recruiting trials for Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

Other University of Washington trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03012282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing